Neutralizing power of blood and nasal antibodies
Study of the Neutralizing Power of Serum Antibodies - 2 (PNAS-2)
This project will test how strong blood and nasal antibodies remain over time in adults getting COVID-19 or monkeypox vaccines or antibody treatments.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Régional d'Orléans Academic / other |
| Locations | 1 site (Orléans) |
| Trial ID | NCT07085611 on ClinicalTrials.gov |
What this trial studies
This monocentric, longitudinal descriptive study will follow adults who receive SARS-CoV-2 or MPXV vaccines or monoclonal antibodies and collect blood and optional nasal swab samples up to 60 months. Laboratory assays will measure neutralizing activity in serum and nasal secretions at multiple time points to map the durability of the humoral response. The protocol is observational and does not change clinical care—samples are collected around vaccination or treatment events. Data will be used to describe how neutralizing power changes over time and in relation to different vaccines or monoclonal products.
Who should consider this trial
Good fit: Adults (18+) who are receiving or planning to receive anti-SARS-CoV-2 and/or anti-MPXV vaccines or monoclonal antibodies and can give informed consent are ideal candidates.
Not a fit: People who are not receiving vaccines or monoclonal antibodies, pregnant or breastfeeding women, those under legal guardianship, or those unable to attend long-term follow-up are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the results could clarify how long antibody-mediated protection lasts and help guide timing of future vaccine doses or antibody treatments.
How similar studies have performed: Prior longitudinal serology studies for SARS-CoV-2 have reliably shown waning neutralizing antibodies and links to protection, while comparable long-term neutralization data for MPXV are more limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (≥18 years) * Patients receiving or scheduled to receive anti-SARS-CoV-2 and/or anti-MPXV vaccines or monoclonal antibodies * Patients have provided written informed consent Exclusion Criteria: * Persons under guardianship or curatorship * Persons under legal protection, * Persons persons deprived of liberty * Persons not affiliated to a social security scheme * Pregnant or breastfeeding women
Where this trial is running
Orléans
- CHU Orléans — Orléans, France (Recruiting)
Study contacts
- Principal investigator: Thierry PRAZUCK, Dr — CHU Orléans
- Study coordinator: Thierry PRAZUCK, Dr
- Email: thierry.prazuck@chu-orleans.fr
- Phone: 0238229593
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.